MX379043B - Uso de sobetirome en el tratamiento de enfermedades de mielinización. - Google Patents

Uso de sobetirome en el tratamiento de enfermedades de mielinización.

Info

Publication number
MX379043B
MX379043B MX2015015228A MX2015015228A MX379043B MX 379043 B MX379043 B MX 379043B MX 2015015228 A MX2015015228 A MX 2015015228A MX 2015015228 A MX2015015228 A MX 2015015228A MX 379043 B MX379043 B MX 379043B
Authority
MX
Mexico
Prior art keywords
sobetirome
myelinization
diseases
treatment
methods
Prior art date
Application number
MX2015015228A
Other languages
English (en)
Other versions
MX2015015228A (es
Inventor
Andrew Placzek
Dennis Bourdette
Gail Marracci
Marco Righi
Meredith Hartley
Priya Chaudhary
Thomas S Scanlan
Original Assignee
Univ Oregon Health & Science
Us Gov Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Us Gov Veterans Affairs filed Critical Univ Oregon Health & Science
Publication of MX2015015228A publication Critical patent/MX2015015228A/es
Publication of MX379043B publication Critical patent/MX379043B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para tratar a un sujeto que tiene o está en riesgo de desarrollar una enfermedad o condición neurodegenerativa asociada con la desmielinización, mielinización insuficiente o subdesarrollo de la vaina de mielina. Los métodos incluyen la administración de una cantidad terapéuticamente efectiva de sobetirome, o una sal farmacéuticamente aceptable del mismo.
MX2015015228A 2013-05-03 2014-02-05 Uso de sobetirome en el tratamiento de enfermedades de mielinización. MX379043B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (2)

Publication Number Publication Date
MX2015015228A MX2015015228A (es) 2016-10-03
MX379043B true MX379043B (es) 2025-03-10

Family

ID=51843844

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015228A MX379043B (es) 2013-05-03 2014-02-05 Uso de sobetirome en el tratamiento de enfermedades de mielinización.
MX2021000538A MX2021000538A (es) 2013-05-03 2015-10-30 Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000538A MX2021000538A (es) 2013-05-03 2015-10-30 Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.

Country Status (12)

Country Link
US (3) US10226438B2 (es)
EP (1) EP2991670B8 (es)
JP (4) JP2016517883A (es)
CN (1) CN105431163A (es)
AU (1) AU2014260468A1 (es)
BR (1) BR112015027682A2 (es)
CA (1) CA2911309A1 (es)
ES (1) ES2745532T3 (es)
MX (2) MX379043B (es)
RU (1) RU2015151216A (es)
SG (2) SG10201709090UA (es)
WO (2) WO2014178892A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
ES2861594T3 (es) 2014-04-30 2021-10-06 Univ Johns Hopkins Composiciones de dendrímeros y su uso en el tratamiento de enfermedades del ojo
AU2015301575B2 (en) 2014-08-13 2018-05-10 The Johns Hopkins University Selective dendrimer delivery to brain tumors
JP7088473B2 (ja) * 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
KR102407059B1 (ko) 2016-04-22 2022-06-10 바이킹 테라퓨틱스 인코포레이티드 갑상선 베타-작용제의 사용
US20190134069A1 (en) * 2016-04-22 2019-05-09 Viking Therapeutics, Inc. Use of thyroid beta-agonists
HUE056357T2 (hu) * 2016-05-18 2022-02-28 Univ Oregon Health & Science Szobetirom származékok
WO2018032012A1 (en) 2016-08-12 2018-02-15 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
CA3061630C (en) 2017-04-27 2021-12-07 The Johns Hopkins University Dendrimer compositions for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
WO2019005816A1 (en) 2017-06-29 2019-01-03 Yale University COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING FIBROUS PULMONARY DISEASES
CN110891583B (zh) * 2017-07-18 2023-06-06 学校法人庆应义塾 针对Th1细胞诱导性细菌的抗菌组合物
EP3707193A1 (en) 2017-11-10 2020-09-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
AU2020232205A1 (en) 2019-03-01 2021-10-21 Autobahn Therapeutics, Inc. Novel thyromimetics
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
CA2240024A1 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
WO1998007435A1 (en) 1996-08-20 1998-02-26 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
PT1089968E (pt) 1998-06-30 2005-08-31 Univ California Analogos de hormona tiroideia e metodos para a sua preparacao
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CN1878545A (zh) * 2003-09-15 2006-12-13 奥德威研究院 甲状腺激素类似物及其使用方法
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
AU2005284879B2 (en) * 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
DK2187882T3 (da) 2007-07-11 2013-04-08 Medicinova Inc Behandling af progressiv neurodegenerativ sygdom med ibudilast
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2010144943A1 (en) 2009-05-20 2010-12-23 Ozpharma Pty Ltd Buccal and/or sublingual therapeutic formulation
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA3115378A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
WO2014063720A1 (en) * 2012-10-25 2014-05-01 Renault Trucks Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用

Also Published As

Publication number Publication date
JP6360552B6 (ja) 2018-08-15
WO2014178931A8 (en) 2015-11-26
MX2015015228A (es) 2016-10-03
US10226438B2 (en) 2019-03-12
WO2014178892A8 (en) 2015-12-17
JP6360552B2 (ja) 2018-07-18
SG11201509012QA (en) 2015-11-27
HK1222552A1 (en) 2017-07-07
US20160081955A1 (en) 2016-03-24
US20200405669A1 (en) 2020-12-31
EP2991670B8 (en) 2019-09-11
SG10201709090UA (en) 2017-12-28
MX2021000538A (es) 2021-04-28
CN105431163A (zh) 2016-03-23
WO2014178892A1 (en) 2014-11-06
ES2745532T3 (es) 2020-03-02
US20190175531A1 (en) 2019-06-13
WO2014178931A1 (en) 2014-11-06
CA2911309A1 (en) 2014-11-06
AU2014260468A1 (en) 2015-11-19
JP2016517884A (ja) 2016-06-20
EP2991670B1 (en) 2019-07-03
BR112015027682A2 (pt) 2017-08-29
EP2991670A1 (en) 2016-03-09
EP2991670A4 (en) 2017-01-18
RU2015151216A (ru) 2017-06-08
US11510887B2 (en) 2022-11-29
JP2018141024A (ja) 2018-09-13
JP2018162321A (ja) 2018-10-18
JP2016517883A (ja) 2016-06-20

Similar Documents

Publication Publication Date Title
MX379043B (es) Uso de sobetirome en el tratamiento de enfermedades de mielinización.
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
LT3740504T (lt) Cd70 kompleksinė terapija
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT
HUE045148T2 (hu) Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére
TR201908151T4 (tr) İzoindolin türevleri.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
HUE069280T2 (hu) Ebselen a Meniere-kór kezelésére történõ felhasználásra
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
MX2017014540A (es) Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus.
LT3362056T (lt) Aminotiolesterio junginiai arba jų farmaciniu požiūriu priimtinos druskos, skirti naudoti vėžio gydyme
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
BR112016028081A2 (pt) Novos compostos como agentes antituberculares